You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PMLBCL(Primary Mediastinal Large B Cell Lymphoma)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

CNS Involvement in Primary Mediastinal Large B-Cell Lymphoma

Active, not recruiting
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • DISEASE
  • (no location specified)
May 4, 2023

Primary Mediastinal Large B-cell Lymphoma With CNS Involvement

Recruiting
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
    • Milan, Italy
      Ospedale San Raffaele
    Aug 29, 2023

    Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell

    Not yet recruiting
    • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
    • +5 more
    • Boston, Massachusetts
    • +1 more
    Jun 28, 2023

    Primary Mediastinal B-cell Lymphoma Trial in Worldwide (observation, 3D-Conformal Radiotherapy (3D-CRT))

    Active, not recruiting
    • Primary Mediastinal B-cell Lymphoma
    • observation
    • 3D-Conformal Radiotherapy (3D-CRT)
    • Louisville, Kentucky
    • +84 more
    Aug 17, 2022

    Lentiviral-based Gene-edited Immune Cell Therapy

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • +4 more
    • Pell's lentiviral-based gene-edited immune cell therapy
    • Kaohsiung, Taiwan
    • +2 more
    Oct 25, 2022

    Large B-cell Lymphoma, DLBCL, Not Otherwise Specified, Primary Mediastinal Large B-cell Lymphoma (PMBCL) Trial (Epcoritamab)

    Available
    • Large B-cell Lymphoma
    • +4 more
    • Epcoritamab
    • (no location specified)
    Feb 16, 2023

    Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Large B-cell Lymphoma Trial in Kaohsiung, Taipei

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • +4 more
    • CD19-targeted chimeric antigen receptor T-cell
    • Kaohsiung, Taiwan
    • +2 more
    Oct 25, 2022

    Cardiovascular Events Among Adults Relapsed or Refractory

    Recruiting
    • Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
    • +9 more
    • Electronic Health Record Review
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 5, 2022

    Communication Training Intervention for Large B-Cell Lymphoma

    Recruiting
    • Lymphoma, B-Cell
    • +5 more
    • Hematolo-GIST Training
    • Participants Appointment
    • New York, New York
    • +2 more
    Jul 3, 2023

    Recurrent DLBCL, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma Trial in Duarte (Biopsy,

    Not yet recruiting
    • Recurrent Diffuse Large B-Cell Lymphoma
    • +11 more
    • Biopsy
    • +5 more
    • Duarte, California
      City of Hope Medical Center
    Jan 3, 2023

    Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent

    Not yet recruiting
    • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
    • +21 more
    • Biopsy
    • +8 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Apr 7, 2023

    Lymphoma, B-Cell Trial in Japan (Pembrolizumab)

    Active, not recruiting
    • Lymphoma, B-Cell
    • Nagoya, Aichi, Japan
    • +8 more
    Aug 18, 2022

    Hematopoietic and Lymphoid Cell Tumor, Recurrent DLBCL, Recurrent High Grade B-Cell Lymphoma Trial in Houston (Anakinra,

    Active, not recruiting
    • Hematopoietic and Lymphoid Cell Neoplasm
    • +8 more
    • Anakinra
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 22, 2022

    Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma Trial in Seattle

    Recruiting
    • Recurrent Diffuse Large B-Cell Lymphoma
    • +8 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Dec 30, 2022

    Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Cyclophosphamide)

    Not yet recruiting
    • Diffuse Large B-cell Lymphoma
    • (no location specified)
    Mar 9, 2023

    B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,

    Recruiting
    • B-Cell Non-Hodgkin Lymphoma
    • +7 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Dec 9, 2022

    Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma Trial in Boston (Adaptive Bridging Radiation Therapy (ABRT))

    Not yet recruiting
    • Lymphoma, B-Cell
    • +7 more
    • Adaptive Bridging Radiation Therapy (ABRT)
    • Boston, Massachusetts
      Dana-Farber Cancer Institute
    Aug 16, 2023

    Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,

    Not yet recruiting
    • Non-hodgkin Lymphoma
    • +9 more
    • CD79b-19 CAR T cells
    • +2 more
    • Boston, Massachusetts
      Massachusetts General Hospital
    Sep 6, 2023

    DLBCL (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)

    Active, not recruiting
    • Diffuse Large B-Cell Lymphoma (DLBCL)
    • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 23, 2023

    B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL Trial in Louisville (Cyclophosphamide, Fludarabine, ACE1831)

    Recruiting
    • B-cell Lymphoma
    • +5 more
    • Louisville, Kentucky
      Norton Cancer Institute
    Jan 24, 2023

    Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Trial

    Active, not recruiting
    • Recurrent B-Cell Non-Hodgkin Lymphoma
    • +7 more
    • Jacksonville, Florida
    • +11 more
    Jan 12, 2023

    Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between

    Not yet recruiting
    • Recurrent ALK Positive Large B-Cell Lymphoma
    • +28 more
    • Biospecimen Collection
    • +5 more
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    Aug 17, 2022

    Diffuse Large B Cell Lymphoma (DLBCL) Trial in Toronto (glofitamab)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma (DLBCL)
    • Toronto, Ontario, Canada
      Princess Margaret Cancer Centre
    Sep 18, 2023

    Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6

    Withdrawn
    • Recurrent Diffuse Large B-Cell Lymphoma
    • +9 more
    • Autologous Hematopoietic Stem Cell Transplantation
    • +5 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Jan 11, 2023

    Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,

    Recruiting
    • Diffuse Large B-cell Lymphoma Recurrent
    • Diffuse Large B Cell Lymphoma Refractory
    • Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
    • Hangzhou, Zhejiang, China
      Zhejiang Cancer Hospital
    Oct 12, 2023